Cipla Loses US Court Appeal In Pet Drug Patent Violation Case
06/07/2012| 08:32am US/Eastern
Recommend:
By Rumman Ahmed
BANGALORE--Indian drug maker Cipla Ltd. (500087.BY) Thursday said it has lost an appeal in a U.S. court over a patent case related to a pet drug.
A lower U.S. court had in June last year ordered the seizure of pet drug PetArmor Plus made by Cipla and Velcera Inc. (VLCR) after ruling the drug violated a patent held by Merial, a unit of French giant Sanofi (SNY), covering Frontline Plus.
The U.S. court of appeals for the federal circuit in Washington D.C. affirmed the order of the district court, Middle District of Georgia, Cipla said in a statement to the stock exchanges.
The district court hasn't yet determined any financial implication of the patent infringement, Cipla said.
Cipla, which was manufacturing the drug on behalf of Velcera, said it was examining options for appealing against the latest order.
Write to Rumman Ahmed at rumman.ahmed@dowjones.com
Recommend :
